drugset / Trial / NCT00642707
Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is: 1. To assess the antiviral activity of PRO 140 2. To assess the safety and tolerability of PRO 140 3. To generate additional PK, PD and safety data of PRO 140
Timeline
- Start
- 2008-03
- Primary completion
- 2008-11
- Completion
- 2008-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Leronlimab | Monoclonal antibody | 162 mg | Subcutaneous |
| Comparator | Leronlimab | Monoclonal antibody | 324 mg | Subcutaneous |